Dark Mode Light Mode

Luton man’s brain tumour shrinks by half in therapy trial

University College London Hospitals NHS Foundation Trust Paul Read stood outside to the left of his wife Pauline. Behind the pair is lots of greenery from plants, trees and grass. Paul and Pauline are stood close together and both face the camera to smile. Paul wears a dark grey jacket with a red shirt and has short white hair. Pauline is wearing a cream denim jacket with a white blouse underneath. She has short white hair with a side fringe coming over her forehead and square framed glasses. University College London Hospitals NHS Foundation Trust

Paul Read was the first patient recruited in a new therapy trial for treating brain tumours

A man’s brain tumour has shrunk by half in a matter of weeks thanks to a new radioactive therapy.

Paul Read, 62, from Luton, was the first patient to take part in a trial aimed at treating glioblastoma, a type of cancer that kills most patients within 18 months.

The therapy, at University College London Hospitals NHS Foundation Trust (UCLH), involved injecting low levels of radioactivity directly into the tumour to kill off cancer cells.

The doctor who designed the trial said the results were “remarkable for somebody whose tumour is so aggressive”.

Surgeons first removed as much tumour as possible before implanting a small medical device, called an Ommaya reservoir, under the scalp.

The drug ATT001, which is given weekly for four to six weeks, is potent over short distances, causing lethal damage to cancer cells while sparing healthy tissue.

University College London Hospitals NHS Foundation Trust Side profile of Paul looking to the right. His scar from brain tumour surgery can we seen clearly and is thin dark purple line in an almost crescent shape. It begins just above his right eyebrow, travels back to his hair, curving down to reach his ear. The scar stops just in front of the middle of Paul's ear. His background is blurred but looks to be a medical setting with plain white walls and a computer. University College London Hospitals NHS Foundation Trust

A doctor said Mr Read’s results were remarkable given how aggressive his tumour was

Mr Read first noticed a severe headache last December and, two weeks later, his face dropped on one side.

He had surgery shortly after his diagnosis to remove as much of the tumour as possible, followed by radiotherapy and chemotherapy.

In July, doctors found the tumour was growing again and he was offered a place on the new CITADEL-123 trial at UCLH.

“I was fully expecting the tumour to return due to its aggressive nature. I know the outcome isn’t great and I was happy to explore anything else,” he said.

“I’m not frightened by any of this. We are all dealt a hand of cards and you don’t know which ones you are going to get.

“It will be wonderful if this treatment helps me and if it doesn’t, it doesn’t… it may benefit someone else down the line.”

‘Really quite remarkable’

The trial was designed by UCLH consultant medical oncologist and chief investigator Dr Paul Mulholland.

He said: “Because it’s targeted directly to the tumour cells, it’s very powerful at killing them.

“We’ve just gone through [Paul’s] scan results with him and his end of treatment scan shows a reduction in the tumour, which is really quite remarkable for somebody whose tumour is so aggressive.”

Dr Mulholland said, as it was the first human study, they had been cautious in their approach, but later hoped to increase the dose of radiation and number of patients.

This article was originally published at www.bbc.com

Keep Up to Date with the Most Important News

Add a comment Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post
Michelle Obama goes after Trump on women’s healthcare: ‘A vote for him is a vote against us’

Michelle Obama’s limitless resentment - Washington Examiner

Next Post
Campus Reform the #1 Source for College News

University of Rochester to offer new ‘Latinx Studies’ major